Skip to main content
Mark Dickson, MD, Oncology, New York, NY

MarkADicksonMD

Oncology New York, NY

Instructor, Medicine, Weill Cornell Medical College

Overview of Dr. Dickson

Dr. Mark Dickson is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Columbia University Vagelos College of Physicians and Surgeons and has been in practice 14 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 89 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 80 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2010
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
  • Columbia University Vagelos College of Physicians and Surgeons
    Columbia University Vagelos College of Physicians and SurgeonsClass of 2003

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • CT State Medical License
    CT State Medical License 2023 - 2025
  • NJ State Medical License
    NJ State Medical License 2020 - 2025
  • NY State Medical License
    NY State Medical License 2010 - 2025
  • NC State Medical License
    NC State Medical License 2020 - 2022
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • TP53 Mutations Emerge with HDM2 Inhibitor SAR405838 Treatment in De-Differentiated Liposarcoma  
    Mark A Dickson, Edwin Choy, Nature

Lectures

  • Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

  • Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
    Aadi Bioscience Breakthrough Therapy Nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComaNovember 14th, 2019
  • Big, Fat Tumors: Liposarcomas Can Top 70 Pounds
    Big, Fat Tumors: Liposarcomas Can Top 70 PoundsOctober 5th, 2018